Alzinova

1,84 SEK

+10,34 %

Mindre end 1K følgere

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+10,34 %

+24,90 %

+31,14 %

+8,77 %

-46,94 %

-52,92 %

-10,05 %

-63,61 %

-74,40 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Markedsværdi

191,54 mio. SEK

Aktieomsætning

5,71 mio. SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

26.2

2026

Årsrapport '25

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelsefor 15 timer siden

DNB Carnegie Access: Alzinova: Memorandum of Understanding for commercial partnership in Saudi Arabia

Selskabsmeddelelsefor 18 timer siden

Alzinova enters memorandum of understanding for commercial partnership

Pressemeddelelse13.11.2025, 17.24

Redeye: Alzinova (Q3 review) - Regulatory progress in anticipation of a deal

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse13.11.2025, 17.18

DNB Carnegie Access: Alzinova: Progress hinges on partnership execution – Q3 review

Pressemeddelelse13.11.2025, 13.07

BioStock: FDA approval and strong data position Alzinova ahead of Phase II

Selskabsmeddelelse13.11.2025, 06.45

Alzinova publishes interim report for January – September 2025

Pressemeddelelse11.11.2025, 13.39

Alzinova to participate at CTAD 2025 with two presentations on ALZ-101

Pressemeddelelse20.10.2025, 08.23

BioStock: Alzinova secures short-term financing – CEO comments

Pressemeddelelse16.10.2025, 08.49

DNB Carnegie Access: Alzinova: Secures short-term loan

Selskabsmeddelelse15.10.2025, 21.48

Alzinova enters into SEK 11 million short-term loan arrangement to secure its working capital needs

Pressemeddelelse7.10.2025, 08.01

BioStock: Alzinova comments on the FDA Fast Track Designation

Pressemeddelelse6.10.2025, 06.38

DNB Carnegie Access: Alzinova: FDA clears ALZ-101 for Fast Track

Selskabsmeddelelse4.10.2025, 08.45

Alzinova Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer’s Disease

Pressemeddelelse25.9.2025, 09.42

BioStock: Video from Alzinova's presentation at BioStock Investing in Life Science – From Seed to Success

Pressemeddelelse5.9.2025, 10.58

BioStock: Alzinova comments on FDA approval ahead of Phase II

Selskabsmeddelelse4.9.2025, 10.30

Alzinova Receives FDA (IND) Approval for Phase II Study of ALZ-101 in Alzheimer’s Disease

Pressemeddelelse2.9.2025, 14.51

DNB Carnegie Access: Alzinova: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Pressemeddelelse29.8.2025, 06.45

Alzinova participates in several industry and investor events during autumn 2025

Eksterne analyser28.8.2025, 11.51

Alzinova: Innovative new approach to Alzheimer’s - Edison

Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer’s disease (AD) via protein modification and immunotherapy-based solutions. Alzinova’s novel AβCC Peptide Technology is designed to target ...

Pressemeddelelse22.8.2025, 11.32

BioStock: Alzinova reports strong half-year scientific and financial progress

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.